title: De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.
abstract: BACKGROUND
  There is a need to develop treatment strategies that are less toxic than BEACOPPescalated x6 cycles, the standard-of-care in advanced Hodgkin's lymphoma patients.
  
  
  OBJECTIVE
  To compare short-term hematological toxicity in advanced Hodgkin's lymphoma patients treated with either BEACOPPescalated x6 cycles (standard group) or BEACOPPescalated x2 followed by ABVD x4 cycles (experimental group).
  
  
  METHODS
  In 27 patients, we compared injections of erythropoiesis stimulating agent and granulocyte colony-stimulating factor, transfusions, hospitalization days, as well as hemoglobin, platelet, leukocyte levels. Method In 27 patients, we compared injections of erythropoiesis stimulating agent and granulocyte colony-stimulating factor, transfusions, hospitalization days, as well as hemoglobin, platelet, leukocyte levels.
  
  
  RESULTS
  The mean number of erythropoiesis stimulating agent and granulocyte colony-stimulating factor injections, platelet transfusions and hospitalization days was significantly lower in the experimental group (erythropoiesis stimulating agents: mean difference -6.6 ± 2.4, p = 0.005; granulocyte colony-stimulating factors: mean difference -8.3 ± 3.6, p = 0.020, platelet transfusions: mean difference -0.6 ± 0.3, p = 0.035; hospitalization days: mean difference: -8.5 ± 1.7 days, p < 10(-3)). There were no differences in terms of red cell transfusions, platelet counts or leukocyte levels between the two groups. From the 3rd chemotherapy cycle, hemoglobin levels decreased to a significantly lesser extent in the experimental group.
  
  
  CONCLUSIONS
  We demonstrated an overall better short-term hematological profile in advanced Hodgkin's lymphoma patients who received a de-escalation chemotherapy regimen with significant differences mainly in terms of hemoglobin levels, erythropoiesis stimulating agent injections, and hospitalization days.
authors.affiliation: Department of Immunology and Internal Medicine, University Hospital, Dijon, France.|Inserm U866, University of Burgundy, Dijon, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Seignez
authors.affiliation: Department of Hematology, University Hospital, Dijon, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Casasnovas
authors.affiliation: Department of Hematology, University Hospital, Dijon, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Ferrant
authors.affiliation: Inserm U866, University of Burgundy, Dijon, France.|Department of Hematology, University Hospital, Dijon, France.
authors.forename: Jean Noel
authors.initials: JN
authors.lastname: Bastie
authors.affiliation: Department of Pharmacy, University Hospital, 14 rue Gaffarel, 21000, Dijon, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Mondoloni
authors.affiliation: Department of Hospital Hygiene and Epidemiology, University Hospital, Dijon, France.
authors.forename: Ludwig Serge
authors.initials: LS
authors.lastname: Aho
authors.affiliation: Department of Pharmacy, University Hospital, 14 rue Gaffarel, 21000, Dijon, France. mathieuboulin@yahoo.fr.|EA4184, University of Burgundy, Dijon, France. mathieuboulin@yahoo.fr.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Boulin
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001803:Blood Transfusion / Q000706:statistics & numerical data; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D006402:Hematologic Diseases / Q000139:chemically induced*; D006454:Hemoglobins / Q000032:analysis; D006689:Hodgkin Disease / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007902:Length of Stay; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D010976:Platelet Count; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D006454:Hemoglobins; D016179:Granulocyte Colony-Stimulating Factor
keywords: ABVD; Advanced Hodgkin’s lymphoma; BEACOPPescalated; Chemotherapy; Hematological toxicity